Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
Chronic myeloid leukemia is a slow progressive tumor, characterized by different phases of disease (chronic, accelerated, and blast). Treatment of chronic myeloid leukemia is dominated by oral BCR-ABL tyrosine kinase inhibitors. Treatment options for newly diagnosed chronic phase disease are dominated by TKIs, including first-to-market Gleevec (Novartis), Sprycel (Bristol-Myers Squibb), and Tasigna (Novartis); treatment options for patients who are resistant or intolerant to prior therapy (and in patients with accelerated and/or blast phase disease) include Bosulif (Pfizer), Iclusig (Ariad), and Synribo (Teva).
Current Treatment: Provides physician insights on prescribing behavior, treatment paths, and the factors and perceptions driving brand usage so you can understand each brand’s performance and improve or defend your competitive position.
Already a Client? Log in to access this report.
Swati Tyagi, is a Senior Business Insight Analyst in the oncology team at the Decision Resources Group. She comes with 8 years of work experience from the life sciences market research industry. She has in-depth expertise in competitive intelligence, secondary and primary research, and strategic projects across multiple oncology indications. Prior to joining the company, she was a delivery manager in a market research organization, where she was handling a major client engagement account and a dedicated team of senior and business analysts working for the specialty medicine brands of the client. She holds an in biotechnology and MBA from Amity University, India.